Angiology | Jotup

Shockwave Intravascular Lithotripsy FDA Approved to Treat Advanced Heart Disease

Retrieved on:

Tuesday, February 16, 2021

Cardiovascular system, Medical specialties, Angiology, Vascular diseases, Heart diseases, Anatomy, Coronary arteries, Coronary artery disease, Artery, Circulatory system, Arteriosclerosis, Atherosclerosis

With this approval, IVL is now commercially available in the United States to treat problematic calcium in the coronary arteries, which can reduce blood flow in the heart.

Key Points:

With this approval, IVL is now commercially available in the United States to treat problematic calcium in the coronary arteries, which can reduce blood flow in the heart.
As coronary artery disease progresses, plaque in the arterial wall often evolves into calcium deposits, which narrow the artery and restrict blood flow.
Intravascular Lithotripsy uses sonic pressure waves, also known as shockwaves, that pass through soft arterial tissue and preferentially disrupt calcified plaque by creating a series of micro-fractures.
Shockwave is focused on developing and commercializing products intended to transform the way calcified cardiovascular disease is treated.

Global Vascular Endothelial Growth Factor (VEGF) Inhibitor Market Report 2020-2030 - ResearchAndMarkets.com

Retrieved on:

Wednesday, February 10, 2021

Health, Pharmaceutical, Branches of biology, Growth factors, Angiology, Vascular endothelial growth factor, VEGF receptor, Angiogenesis inhibitor, VEGFR-2 inhibitor

The "Vascular Endothelial Growth Factor (VEGF) Inhibitor Global Market Report 2020-30: COVID-19 Growth and Change" report has been added to ResearchAndMarkets.com's offering.

Key Points:

The "Vascular Endothelial Growth Factor (VEGF) Inhibitor Global Market Report 2020-30: COVID-19 Growth and Change" report has been added to ResearchAndMarkets.com's offering.
The vascular endothelial growth factor (VEGF) inhibitor market consists of sales of vascular endothelial growth factor (VEGF) inhibitor biosimilars.
Vascular endothelial growth factor (VEGF)/vascular endothelial growth factor (VEGFR) inhibitors are agents that inhibit VEGF and VEGFR activity.
Global Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation by Drugs Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

Beyond Air® Reports Financial Results for Third Quarter of Fiscal Year 2021 and Provides Business Update

Retrieved on:

Tuesday, February 9, 2021

Angiology, Anatomy, Branches of biology, Forward-looking statement, Lung, Vascular smooth muscle, Blood vessel, Artery, Respiratory tract

Additionally, Beyond Air is using ultra-high concentrations of NO with a proprietary delivery system to target certain solid tumors in the pre-clinical setting.

Key Points:

Additionally, Beyond Air is using ultra-high concentrations of NO with a proprietary delivery system to target certain solid tumors in the pre-clinical setting.
In the airways, NO targets the vascular smooth muscle cells that surround the small resistance arteries in the lungs.
Forward-looking statements include statements about our expectations, beliefs, or intentions regarding our product offerings, business, financial condition, results of operations, strategies or prospects.
Rather, forward-looking statements relate to anticipated or expected events, activities, trends or results as of the date they are made.

Trefoil Therapeutics Begins Second Phase 2 “STORM” Clinical Trial with Regenerative Treatment for Fuchs Endothelial Corneal Dystrophy

Retrieved on:

Tuesday, February 9, 2021

Trefoil Therapeutics today announced it has begun a Phase 2 clinical trial of its engineered Fibroblast Growth Factor-1, TTHX1114, to evaluate its safety and efficacy as a regenerative treatment for patients with Fuchs Endothelial Corneal Dystrophy (FECD).

Key Points:

Trefoil Therapeutics today announced it has begun a Phase 2 clinical trial of its engineered Fibroblast Growth Factor-1, TTHX1114, to evaluate its safety and efficacy as a regenerative treatment for patients with Fuchs Endothelial Corneal Dystrophy (FECD).
The multi-center clinical trial is an open label study involving 40 or more patients already scheduled for DSO surgery.
Endpoints being assessed in the study include endothelial recovery, corneal edema & clearing and visual acuity improvement after DSO surgery.
TTHX1114 has been shown in preclinical studies to stimulate endothelial cell proliferation and migration, and drive regeneration of the corneal endothelial layer.

Dr. Stanley Rockson Joins Koya Medical as Chief Medical Officer

Retrieved on:

Thursday, February 4, 2021

Angiology, Branches of biology, Medical specialties, Lymphedema, Veins, Venous insufficiency, Edema

OAKLAND, Calif., Feb. 4, 2021 /PRNewswire/ --Koya Medical ( www.koyamedical.com ), a healthcare company focused on developing breakthrough treatments for lymphedema and venous disorders, announced the appointment of Stanley G. Rockson, MD as its Chief Medical Officer.

Key Points:

OAKLAND, Calif., Feb. 4, 2021 /PRNewswire/ --Koya Medical ( www.koyamedical.com ), a healthcare company focused on developing breakthrough treatments for lymphedema and venous disorders, announced the appointment of Stanley G. Rockson, MD as its Chief Medical Officer.
Dr. Stanley G. Rockson is the Professor and Chief of Consultative Cardiology and the Director of the Stanford Center for Lymphatic and Venous Disorders at Stanford University.
"Dayspring is an important new advancement to help treat patients with lymphedema and venous disease," said Dr. Rockson.
Koya Medical received FDA clearance for Koya Dayspring, a prescription only active wearable compression system for the treatment of lymphedema and venous insufficiency.

Exonate announces the initiation of Phase Ib/II clinical trial for Diabetic Macular Oedema, as part of its collaboration with Janssen

Retrieved on:

Tuesday, February 2, 2021

Branches of biology, Medical specialties, Organ systems, Angiology, Vascular endothelial growth factor, Diabetic retinopathy, Retinopathy, Retina, Neovascularization, Anti–vascular endothelial growth factor therapy, Vascular endothelial growth factor A

Dr Catherine Beech, Chief Executive Officer of Exonate, said: "The initiation of our first clinical trial is an important step in the validation of our eye drop approach.

Key Points:

Dr Catherine Beech, Chief Executive Officer of Exonate, said: "The initiation of our first clinical trial is an important step in the validation of our eye drop approach.
The collaboration with Janssen has been incredibly positive and together, we have designed a study that we believe will deliver meaningful results."
By exploiting the alternative splicing of Vascular Endothelial Growth Factor (VEGF), Exonate has developed small-molecules for the treatment of retinal neovascular diseases.
Although DMO is more likely to occur as diabetic retinopathy worsens, it can happen at any stage of the disease.

Gemini Therapeutics Announces Initiation of GEM103 Phase 2a Study as an Add-On to Anti-VEGF Therapy for the Treatment of Wet AMD Patients at Risk for Progressive Vision Loss Due to Macular Atrophy

Retrieved on:

Monday, February 1, 2021

Health, Genetics, Clinical trials, Pharmaceutical, Optical, Biotechnology, Branches of biology, Biology, Vascular endothelial growth factor, Macular degeneration, Angiology, Anti–vascular endothelial growth factor therapy, GEM103, Wet Age-Related Macular Degeneration (AMD), Gemini Therapeutics

Current anti-VEGF therapies have improved the quality of life for patients with wet AMD, said Marc E. Uknis, M.D., F.A.C.S., Chief Medical Officer of Gemini Therapeutics.

Key Points:

Current anti-VEGF therapies have improved the quality of life for patients with wet AMD, said Marc E. Uknis, M.D., F.A.C.S., Chief Medical Officer of Gemini Therapeutics.
Wet AMD affects approximately 1.4 million people in the United States, and GEM103 is uniquely suited to correct CFH insufficiency associated with VEGF inhibition.
The clinical trial will be a randomized, single-masked, and sham-controlled study of patients requiring ongoing VEGF inhibition for wet AMD.
GEM103 is currently in a Phase 2a trial in dry AMD patients with a CFH risk variant.

Outlook on the Vascular Patches Global Market to 2025 - Increasing Adoption of Biological Patches is Driving Growth - ResearchAndMarkets.com

Retrieved on:

Friday, January 29, 2021

Medical devices, Health, Medical specialties, Anatomy, Angiology, Gross pathology, Vascular surgery, Vascular diseases, IgG4-related disease, Aneurysm, Aortic aneurysm, Pseudoaneurysm, Aorta, Open aortic surgery

A small, localized saccular pseudoaneurysm of the aorta is often treated with quick patch repair rather than tube graft replacement.

Key Points:

A small, localized saccular pseudoaneurysm of the aorta is often treated with quick patch repair rather than tube graft replacement.
This factor is also expected to increase the incidence of aortic aneurysm, which will increase the demand for vascular patches, helping in the market growth.
North America holds the largest share in the vascular patches market, with the United States being the largest contributor to its revenue.
Additionally, the increasing prevalence of vascular diseases is the major factor expected to drive the overall growth of the market, during the forecast period.

PEDRA™ Technology Receives FDA Breakthrough Device Designation for its PEDRA™ Xauron™ Real-Time Tissue Perfusion System

Retrieved on:

Monday, January 25, 2021

Cardiovascular system, Circulatory system, Medical specialties, Ischemia, Angiology, Chronic limb threatening ischemia, Hypertension, Perfusion, Revascularization, Peripheral artery disease, Acute limb ischaemia, CLI

SINGAPORE, Jan 25, 2021 /PRNewswire/ -- PEDRA Technology , a privately-held company, announced today that the U.S Food and Drug Administration (FDA) has granted the company a Breakthrough Device Designation for the periprocedural use of its PEDRA Xauron Perfusion System in the treatment of critical limb threatening ischemia (CLTI).

Key Points:

SINGAPORE, Jan 25, 2021 /PRNewswire/ -- PEDRA Technology , a privately-held company, announced today that the U.S Food and Drug Administration (FDA) has granted the company a Breakthrough Device Designation for the periprocedural use of its PEDRA Xauron Perfusion System in the treatment of critical limb threatening ischemia (CLTI).
"This Breakthrough Device Designation recognizes the compelling need for real-time tissue perfusion monitoring during lower limb revascularization procedures for the treatment of CLTI.
To my knowledge, this is the first perfusion monitor for CLTI that has received this designation," said Kareen Looi, CEO of PEDRA Technology.
PEDRA Technology is a medical device company that focuses on the use of tissue perfusion monitoring in the field of peripheral artery disease (PAD) and critical limb ischemia (CLI).

Inari Medical Announces Presentation of Positive Chronic Clot Subanalysis Results from Real World CLOUT Registry at LINC 2021

Retrieved on:

Monday, January 25, 2021

Angiology, Medicine, Cardiovascular system, Thrombolysis, Chronic condition, Vein, Post-thrombotic syndrome, Hematology, Deep vein thrombosis

Be it on-going COVID fears, delays in diagnosis or impediments to referral, many DVT patients have chronic disease by the time they finally meet a DVT interventionist.

Key Points:

Be it on-going COVID fears, delays in diagnosis or impediments to referral, many DVT patients have chronic disease by the time they finally meet a DVT interventionist.
These physicians know that chronic clot is more wall-adherent and collagen-rich, rendering traditional lytic-based tools ineffective, said Dr. Abramowitz.
The CLOUT chronic subanalysis has shown us that ClotTriever can offer these chronic DVT patients hope, removing a median 90% of their clot in a single session without the use of thrombolytics.
Inari Medical, Inc. is a commercial-stage medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases.